Abstract
The discovery of new prognostic factors proceeds at a much more rapid pace than our knowledge of how to properly utilize this information in the management of patients with breast cancer, especially those with early breast cancer that has not metastasized to regional lymph nodes. Prognostic factors provide information on how the patient is likely to do regardless of treatment. Predictive factors provide information on whether a patient is likely to benefit from therapy. Most factors identified to date provide prognostic information, but relatively few provide information that is truly helpful in making a therapeutic decision in the management of individual patients. In large part this is because there has been insufficient study of the factor, especially prospective evaluations of the factor. Unfortunately this has resulted in the premature use of this information under the general rubric that patients with a poor prognosis deserve more treatment in spite of the fact that there may be no benefit from that therapy in the poor prognostic group.
Similar content being viewed by others
References
Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 302:17-30/78–90, 1980
Sasaki GH, Leung BS, Fletcher WS: LevoDopa test and estrogen receptor assay in prognosticating responses of patients with advanced cancer of the breast to endocrine therapy. Ann Surg 183:392-396, 1976
Sluyser M, Van Nie R: Estrogen receptor content and hormone-responsiveness of growth of mouse mammary tumors. Cancer Res 34:3253-3257, 1974
Byar D, Sears M, McGuire W: Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 15:299-310, 1979
Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet i:995-997, 1979
Fletcher W, Leung B, Davenport C: The prognostic significance of estrogen receptors in human breast cancer. Am J Surg 135:372-374, 1978
Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979
Holdaway IM, Mountjoy KG: Progesterone and oestrogen receptors in human breast cancer. Austr NZ J Med 8:630-638, 1978
Kern WH: Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast. Surg Gynecol Obstet 148:240-242, 1979
Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
Lippman ME, Allegra JC, Thompson EG, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
Hayes D: Serum (circulating) tumor markers for breast cancer. Rec Results Cancer Res 140:101-131, 1996
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177-182, 1987
Spiegel D, Bloom JR, Kraemer HC, Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2:888-891, 1989
Kogon MM, Biswas A, Pearl D, Carlson RW, Spiegel D: Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cancer 80:225-230, 1997
Spiegel D: Cancer and depression [review]. Br J Psych Suppl 30:109-116, 1996
Gasparini G, Bevilacqua P, Dal Fior S, Panizzoni GA, Favretto S, Visona A, Meli S: Characterization of node-negative breast cancer by clinico-pathologic and biologic factors. Anticancer Res 10:205-208, 1990
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71–85, 1992
Henderson IC: Adjuvant systemic therapy for early breast cancer. Cancer 74:401-409, 1994
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076-1087, 1988
Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73:1545-1551, 1996
Osborne CK: Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases, Second Edition. Lippincott, Philadelphia, 1991, pp 301-325
Press M, Hung G, Godolphin W, Slamon D: Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
Thor A, Schwartz L, Koerner F, Edgerton S, Skates S, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147-7152, 1989
Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin H, Isola J: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
Lovekin C, Ellis I, Locker A, Robertson J, Bell J, Nicholson R, Gullick W, Elston C, Blamey R: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
McCann A, Dervan P, O'Regan M, Codd M, Gullick W, Tobin B, Carney D: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303, 1991
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam D-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y: c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69:2953-2960, 1992
Tanner B, Freidberg T, Itze M, Beck T, Oesch F, Knapstein P-G: c-erbB-2 oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. Gynecol Oncol 47:228-233, 1992
Yuan J, Hennessy C, Givan A, Corbett I, Henry J, Sherbet G, Lennard T: Predicting outcome for patients with node negative breast cancer; a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br J Cancer 65:461-465, 1992
Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S: Prognostic significance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer 67:625-629, 1993
Press M, Pike M, Chazin V, Hung F, Udove J, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson M, Slamon D: Her2-neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
Gasparini G, Gullick W, Maluta S, Palma P, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine N, Bevilacqua P: c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma — an immunocytochemical study. Eur J Cancer 30A:16-22, 1994
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco A, De Placido S: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
Molland J, Barraclough B, Gebski V, Milliken J, Bilous M: Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. Aust NZ J Surg 66:64-70, 1996
Andrulis I, Bull S, Blackstein M, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16:1340-1349, 1998
Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
Giai M, Roagna R, Ponzone R, de Bortoli M, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 14:1441-1450, 1994
Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J: The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35:283-291, 1995
Borg Å, Tandon A, Sigurdsson H, Clark G, Fernö M, Fuqua S, Killander D, McGuire W: Her2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337, 1990
Têtu B, Brisson J: Prognostic significance of HER2/neu oncoprotein expression in node-positive breast cancer. Cancer 73:2359-2365, 1994
Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
Hartmann L, Ingle J, Wold L, Farr GH J, Grill J, Su J, Maihle N, Krook J, Witzig T, Roche P: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963, 1994
Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S: A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 48:21-32, 1998
Lippman ME, Weisenthal LM, Paik SM, Nagourney RA, Kern DH: erbB-2 positive specimens from previously-untreated breast cancer patients have in vitro drug resistance profiles which resemble profiles of specimens obtained from patients who have previously failed combination chemotherapy. Proc ASCO 9:24, 1990
Thor A, Budman D, Berry D, Muss H, Kute T, Barcos M, Cirrincione C, Edgerton S, Weiss R, Ferree C, Allred C, Wood W, Frei E III, Henderson I, Norton L, Liu E: Selecting patients for higher dose adjuvant CAF: c-erbB-2, p53, dose and dose intensity in stage II, node+ breast cancer (CALGB 8869 and 8541). Proc ASCO 16:A452, 1997
Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet i:588-591, 1984
Fisher ER, Gregorio R, Redmond C, Dekker A, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). Am J Clin Pathol 65:21-30, 1976
Fisher E, Swamidoss S, Lee C, Rockette H, Redmond C, Fisher B: Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42:2025-2031, 1978
Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551-1557, 1983
Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW: Axillary micro-and macrometastases in breast cancer. Ann Surg 194:585-591, 1981
Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989
Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990
Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC, Osborne CK: Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12:467-474, 1994
Rockette HE, Caplan RJ: Heterogeneous treatment effects — strategies for subgroup analysis in clinical trials. Rec Results Cancer Res 111:49-54, 1988
Hilsenbeck SG, Ravdin PM, de Moor CA, Osborne CK, Clark GM: Paradoxical decreases in prognostic utility as datasets mature: time-dependent lack of proportional hazards in prognostic factors in primary breast cancer [abstract]. Breast Cancer Res Treat 37:35, 1996
Hilsenbeck S, Clark G, McGuire W: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197-206, 1992
McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
Clark G, Hilsenbeck S, Ravdin P, Di Laurentiis M, Osborne C: Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Res Treat 32:105-112, 1994
Henderson IC: Prognostic factors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases (2nd ed). Lippincott, Philadelphia, 1991, pp 332-346
Levine M, Browman G, Gent M, Roberts R, Goodyear M: When is a prognostic factor useful?: a guide for the perplexed. J Clin Oncol 9:348-356, 1991
McGuire WL, Tandon AK, Allred C, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990
Gasparini G, Pozza F, Harris A: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
Koenders P, Beex L, Kienhui C, Kloppenborg P, Benraad T: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 25:21-27, 1993
Seshadri R, McLeay W, Horsfall D, McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69:23-27, 1996
Pujol P, Maudelonde T, Daures J-P, Rouanet P, Brouillet J-P, Pujol H, Rochefort H: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71:2006-2012, 1992
Ciocca D, Clark G, Tandon A, Fuqua S, Welch W, McGuire W: Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer. J Natl Cancer Inst 85:570-574, 1993
Ravdin PM, Clark GM: A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 22:285-293, 1992
Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WL: A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat 21:47-53, 1992
Masters JRW, Camplejohn RS, Millis RR, Rubens RD: Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. Br J Cancer 55:455-457, 1987
Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81:1383-1387, 1989
Fisher ER, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Cancer Project: VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 51:181-191, 1983
Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71:1029-1032, 1995
Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292-300, 1996
Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, et al: Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 22:297-306, 1995
Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62:513-515, 1979
Silvestrini R, Daidone MG, Valagussa P, Salvadori B, Rovini D, Bonadonna G: Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 71:375-379, 1987
Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P, Di Fronzo G, Silvestrini R: Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1:45-49, 1986
Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD: Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an Intergroup study (INT 0076). JNCI Monographs 11:167-72, 1992
O'Reilly SM, Barnes DM, Camplejohn RS, Millis RR, Bartkova J, Rubens RD, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction (SPF) and prognosis in breast cancer. Proc ASCO 9:18, 1990
Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbraglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS, Wheeler JE: Interobserver reproducibility of histopathological features in Stage II breast cancer: An ECOG study. Breast Cancer Res Treat 5:3-10, 1985
Spyratos F, Briffod M, Tubiana-Hulin M, Andrieu C, Mayras C, Pallud C, Lasry S, Rouesse J: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up. Cancer 69:470-475, 1992
O'Reilly SM, Richards MA: Is flow cytometry a useful investigation in breast cancer? Eur J Cancer 28:504-507, 1992
Briffod M, Spyratos F, Tubiana-Hulin M, Pallud C, Mayras C, Filleul A, Rouesse J: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma: cytomorphologic changes, initial tumor ploidy, and tumor regression. Cancer 63:631-637, 1989
Barnes DM: Cyclin D1 expression and prognosis in mammary carcinoma. Proc AACR 37:A1418, 1996
Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G: Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 9:1633-1640, 1994
Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92-99, 1996
McIntosh G, Anderson J, Milton I, Steward M, Parr A, Thomas M, Henry J, Angus B, Lennard T, Horne C: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891, 1995
Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728-734, 1996
Pelosio P, Barbareschi M, Benoldi E, Marchetti A, Verderio P, Caffo O, Bevilacqua P, Borracchi P, Buttitta F, Barbazza R, Palma P, Gasparini G: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7:695-703, 1996
Seshadri R, Lee C, Hui R, McCaul K, Horsfall D, Sutherland R: Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2:1174-1184, 1996
van Diest PJ, Michalides RJ, Jannink J, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP: Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150:705-711, 1997
Silvestrini R, Benini E, Veneroni S, Daidone M, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
Silvestrini R, Veneroni S, Benini E, Luisi A, Leutner M, Maucione A, Kenda R, Zucali R, Veronesi U: Expression of p53, glutathione S-transferase-1, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639-45, 1997
van Slooten H-J, Clahsen P, van Dierendonck J, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van de Velde C, van de Vijver M: Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Brit J Cancer 74:78-85, 1996
Lê M, Mathieu M, Llombart-Cussac A, Abd el Al H, Spielman M, Riou G: Prognostic value of bcl-2 expression in operable breast cancer patients. Proc ASCO 16:A483, 1997
Schroeder W, Biersterfield S, Zillessen S, Rath W: Epidermal growth factor receptor — immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17:2799-2802, 1997
Torregrosa D, Bolufer P, Lluch A, López J, Barragán E, Ruiz A, Guillem V, Munárriz B, García Conde J: Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 262:99-119, 1997
Hawkins R, Tesdale A, Killen M, Jack W, Chetty U, Dixon J, Hulme M, Prescott R, McIntyre M, Miller W: Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 74:1469-1478, 1996
Bolla M, Chedin M, Colonna M, Marron-Charrière J, Rostaing-Puissant B, Pasquier D, Panh M, Winckel P, Chambaz E: Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters. Breast Cancer Res Treat 29:265-270, 1994
Delarue JC, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G: Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173-178, 1988
Fox SB, Smith K, Hollyer J, Greenhall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognoste marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41-49, 1994
Gasparini G, Borazzio P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N: A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat 29:59-71, 1994
Klijn J, Look M, Portengen H, Alexieva-Figusch J, van Putten W, Foekens J: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83, 1994
Nicholson R, McClelland R, Gee J, Manning D, Cannon P, Robertson J, Ellis I, Blamey R: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125, 1994
Noguchi M, Mizukami Y, Kinoshita K, Earashi M, Thomas M, Miyazaki I: The prognostic significance of epidermal growth factor receptor expression in breast cancer. Surg Today 24:889-894, 1994
Spyratos F, Martin P, Hacène K, Andrieu C, Romain S, Floiras J, Magdelènat H: Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study. Breast Cancer Res Treat 29:85-95, 1994
Toi M, Tominaga T, Osaki A, Toge T: Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat 29:51-58, 1994
Iwase H, Kobayashi S, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Naito A, Yamashita T, Itoh K, Masaoka A: Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res Treat 28:215-221, 1993
Murray P, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes R: The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67:1408-1412, 1993
Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323-326, 1992
Sauer R, Schauer A, Rauschecker H, Schumacher M, Gatzemeier W, Sauerbrei W, Dunst J, Seegenschmiedt M, Marx D, et al: Breast preservation versus mastectomy in early breast cancer — 1991 update of the GBSG 1 — protocol and prognostic factors. Strahl Onkol 168:191-202, 1992
Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon J, Harris A: Epidermal growth factor receptor (EGFr); results of a 6-year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146-150, 1991
Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977-980, 1991
Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65:1980-1984, 1990
Lewis S, Locker A, Todd J, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385-389, 1990
Spyratos F, Delarue J-C, Andrieu C, Lidereau R, Champéme M-H, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83-89, 1990
Foekens J, Portengen H, van Putten W, Trapman A, Reubi J-C, Alexieva-Figusch J, Klijn J: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989
Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77-90, 1989
Harris AL, Nicholson S, Sainsbury JRC, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34:123-131, 1989
Sainsbury JRC, Nicholson S, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) status. A clinically useful prognostic indicator in axillary node negative breast cancer [abstract]. Breast Cancer Res Treat 14:133, 1989
Costa S, Stamm H, Alemendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U: Predictive value of EGF receptor in breast cancer. Lancet ii:1258, 1988
Nicholson S, Halcrow P, Sainsbury JRC, Angus B, Chambers P, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58:810-814, 1988
Rios MA, Macias A, Perez R, Lage A, Skoog L: Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8:173-176, 1988
Sainsbury JRC, Farndon JR, Needham GK, Harris AL, Malcolm AJ: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398-1402, 1987
Schwartz L, Koerner F, Edgerton S, Sawicka J, Rio M-C, Bellocq J-P, Chambon P, Thor A: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51:624-628, 1991
Henry J, Piggott N, Mallick U, Nicholson S, Farndon J, Westley B, May F: pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63:615-622, 1991
Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239-248, 1993
Luqmani YA, Ricketts D, Ryall G, Turnbull L, Law M, Coombes RC: Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer 54:619-623, 1993
Wilson Y, Rhodes M, Ibrahim N, Padfield C, Cawthorn S: Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg 81:1155-1158, 1994
Soubeyran I, Quènal N, Coindre J-M, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Brit J Cancer 74:1120-1125, 1996
Besse G, Kwiatkowski F, Gaillard G, Daver A, Dalifard I, Basuyau J, Brunelle P, Wafflart J, Angibeau R, Auvray E, Goussard J: Rôle prognostique de la protéine pS2 dans 1065 cas de cancer du sein. Étude multicentrique. Bull Cancer 81:289-296, 1994
MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in invasive breast carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, sP2, and GST1. Br J Cancer 74:1458-1465, 1996
Predine J, Spyratos F, Prud'homme J, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzymelinked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 69:2116-2123, 1992
Crombach G, Ingerhorst A, Göhring U-J, Scharl A, Möbus V, Schaeffer H-J: Expression of pS2 protein in breast cancer. Arch Gynecol Obstet 253:183-192, 1993
Göhring U-J, Scharl A, Ahr A: Immunohistochemical detection of receptors, proteases, tumour suppressor proteins and proliferating markers as prognostic indicators for primary breast cancer patients. Geburtsch Frauenheilk 56:177-183, 1996
Thor A, Koerner F, Edgerton S, Wood W, Stracher M, Schwartz L: pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival. Breast Cancer Res Treat 21:111-119, 1992
Foekens J, Schmitt M, van Putten W, Peters H, Kramer M, Jänicke F, Klijn J: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994
Foekens J, Rio M-C, Seguin P, van Putten W, Fauque J, Nap M, Klijn J, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50:3832-3837, 1990
Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G: pS2 in breast cancer — alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68:374-379, 1993
Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30A:5-11, 1994
Speiser P, Stolzechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R: pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 14:2125-2130, 1994
Thompson A, Hawkins R, Elton R, Steel C, Chetty U, Carter D: pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 68:93-96, 1993
Clahsen P, van de Velde C, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van de Broek L, Sahmoud T, van de Vijver M: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479, 1998
Formenti S, Dunnington G, Lenz H, Russell C, Silberman H, Spicer D, Groshen S, Watkins K, Muggia F: Original p53 status predicts for pathological response to 5-fluorouracil and radiation in locally advanced breast cancer. Proc ASCO 16:A590, 1997
Acenero M, González J, Ballesteros P: Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiological factors, histologic features and prognosis. Gen Diag Pathol 142:289-296, 1996
Eissa S, Khalifa A, El-Gharib A, Salah N, Mohamed M: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res 17:1417-1424, 1997
Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Dalla Palma P, Harris A, Barbareschi M: Prognostic value of p21WAF21 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 2:1591-1599, 1996
Charpin C, Garcia S, Bouvier C, Andrac L, Devictor B, Lavaut M-N, Allasia C, Bonnier P, Piana L: Quantitative immunocytochemical assays on frozen sections of p53. Correlation to the follow-up of patients with breast carcinomas. Anat Pathol 106:640-646, 1996
Katoh A, Breier S, Stemmler N, Specht S, Blanock K, D'Amico F: p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Anticancer Res 16:1301-1304, 1996
Hou M-F, Huang T-J, Huang C-J, Huang Y-S, Hsieh J-S, Lin S-J: Expression of p53 protein and its prognostic significance in breast cancer patients. Kaohsiung J Med Sci 12:471-478, 1996
Regidor P, Regidor M, Callies R, Schindler A: Detection of p53 auto-antibodies in the sera of breast cancer patients with new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Eur J Gynaec Oncol 17:192-199, 1996
Silvestrini R, Benini E, Daidone M, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
Willsher P, Pinder S, Robertson L, Nicholson R, Ellis I, Bell J, Blamey R, Green J, Robertson J: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16:927-930, 1996
Archer S, Eliopoulos A, Spandidos D, Barnes D, Ellis I, Blamey R, Nicholson R, Robertson J: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first-line hormonal therapy. Br J Cancer 72:1259-1266, 1995
Bland K, Konstadoulakis M, Vezeridis M, Wanebo H: Oncogene protein co-expression. Value of Ha-ras, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221:706-720, 1995
Daidone M, Silvestrini R, Benini E, Luisi A: Biologic variables could predict specific relapse types in node-negative breast cancer. Anticancer Res 15:1825, 1995
Elledge R, Gray R, Mansour E, Yu Y, Clark G, Ravdin P, Osborne C, Gilchrist K, Davidson N, Robert N, Tormey D, Allred D: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
Göhring U-J, Scharl A, Heckel C, Ahr A, Crombach G: p53 protein in 204 patients with primary breast carcinoma — immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet 256:139-146, 1995
Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751, 1995
Kristen P, Müller JG, Caffier H: Prognostic relevance of p53 in node negative breast cancer. Anticancer Res 17:2869-2871, 1997
Mathieu M-C, Koscielny S, Bihan M-CL, Spielmann M, Arrigada R: No relation between p53 and response to chemotherapy [letter]. Lancet 345:1182, 1995
Veronese S, Saladini L, Cannone M, Gamacorta M: Biological parameters and prognosis in breast cancer. Anticancer Res 15:1827, 1995
Koechli O, Schauer G, Selfert B, Hornung R, Haller U, Eppenberger U, Mueller H: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344:1647-1648, 1994
Noguchi M, Kitagawa H, Kinoshita K, Thomas M, Matsuo I, Saito Y, Mizakami Y, Nonomura A, Michigishi T, Nakamura S: The relationship of p53 protein and lymph node metastases in invasive breast cancer. Surg Today 24:512-517, 1994
Allred D, Clark G, Elledge R, Fuqua S, Brown R, Chamness G, Osborne C, McGuire W: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
Barnes D, Dublin E, Fisher C, Levinson D, Millis R: Immunohistochemical detection of p53 protein in mammary carcinoma. An important new independent indicator of prognosis? Hum Pathol 24:469-476, 1993
Thorlacius S, Børresen A-L, Eyfjörd J: Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53:1637-1641, 1993
Isola J, Visakorpi T, Holli K, Kallionemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
Poller D, Hutchings C, Galea M, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583-588, 1992
Thor A, Moore D, Edgerton S, Kawasaki E, Reihsaus E, Lynch H, Marcus J, Schwartz L, Chen L-C, Mayall B, Smith H: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835-840, 1991
Ostrowski J, Sawan A, Henry L, Wright C, Henry J, Henessy C, Lennard T, Angus B, Horne C: p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164:75-81, 1991
Chamness GC, Ruiz A, Fulcher L, Clark GM, McGuire WL: Stress response protein srp27 predicts recurrence in node-negative breast cancer. Breast Cancer Res Treat 12:130, 1988
Chamness GC, Ruiz A, Fulcher L, Clark G, Fuqua S, McGuire W: Estrogen-inducible heat shock protein hsp27 predicts recurrence in node-negative breast cancer. Proc AACR 30:252, 1989
Porter P, Malone K, Heagerty P, Alexander G, Gatti L, Firpo E, Daling J, Roberts L: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225, 1997
Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galuzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer 57:1259-1263, 1997
Panel ATME: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996
Sastre-Garau X, Lacombe M, Jouve M, Véron M, Magdelénat H: Nucleoside diphosphate kinase/nm23 expression in breast cancer: lack of correlation with lymph node metastasis. Int J Cancer 50:533-538, 1992
Tokunaga Y, Urano T, Furukawa K, Kondo H, Kanematsu T, Shiku H: Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer 55:66-71, 1993
Barnes R, Masood S, Barker E, Rosengard A, Coggin D, Crowell T, King C, Porter-Jordan K, Wargotz E, Liotta L, Steeg P: Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 139:245-250, 1991
Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ: Expression of the antimetastatic gene nm23 in human breast cancer: An association with good prognosis. J Natl Cancer Inst 83:281-285, 1991
Bevilacqua G, Sobel M, Liotta L, Steeg P: Association of low nm23 RNA levels in human primary infiltrating ductal carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989
Granata G, Coradini D, Cappelletti V, DiFronzo G: Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27:970-972, 1991
Han S, Yun I, Noh D, Choe K, Song S, Chi J: Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 65:22-27, 1997
Namer M, Ramaioli A, Fontana X, Etienne M-C, Hery M, Jourlait A, Milano G, Frenay M, François E, Laplaus F: Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19:85-93, 1991
Kute T, Shao Z-M, Sugg N, Long R, Russell G, Case L: Cathepsin D as a prognostic indicator for node negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52:5198-5203, 1992
Spyratos F, Martin P-M, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Doussal VL, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992
Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Horne CHW: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer: An immunohistochemical study. Cancer 65:265-271, 1990
Alex G, Neises M, Lenz F, Melchert F: The value of new prognostic factors for the prediction of diseasefree interval for women with primary breast cancer in comparison with histopathological variables. Eur J Cancer 33:A 896, 1997
Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A: Clinical significance of cathepsin D assay in breast cancer tissues. J Surg Oncol 60:221-226, 1995
Eng Tan P, Benz C, Dollbaum C, Moore D, Edgerton S, Zava D, Thor A: Prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 5:329-336, 1994
Castiglioni T, Merino M, Elsner B, Lah T, Sloane B, Emmert-Buck M: Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Human Pathol 25:857-862, 1994
Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
Charpin C, Garcia S, Bouvier C, Martinin F, Lavaut M, Allasia C, Bonnier P, Andrac L: Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival. J Clin Pathol 50:586-590, 1997
Göhring U-J, Scharl A, Thelen U, Crombach G, Titus B-R: Prognostic value of cathepsin D in breast cancer: comparison in immunohistochemical and immunoradiometric detection methods. J Clin Pathol 49:57-64, 1996
Visscher D, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman J: Immunohistochemical evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 6:302-306, 1993
Winstanley J, Leinster S, Cooke T, Westley B, Platt-Higgins A, Rudland P: Prognostic significance of cathepsin D in patients with breast cancer. Br J Cancer 67:767-772, 1993
Romain S, Muracciole X, Varette I, Bressac C, Brandone H, Martin P: La cathepsine-D: un facteur prognostique indèpendant dans le cancer du sein. Bull Cancer 77:439-447, 1990
Jänicke F, Schmitt M, Graeff H: The urokinase-type plasminogen activator (u-PA) is related to early relapse in breast cancer. Br J Cancer s62:5, 1990
Grøndahl-Hansen J, Christensen I, Rosenquist C, Brünner N, Mouridsen H, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993
Harbeck N, Thomssen C, Henselmann B, Dettmar P, Prechtl A, Pache L, Kuhn W, Höfler H, Jänicke F, Schmitt M, Graef H: Long-term prognostic impact of PAI-1 in primary breast cancer confirmed by six-year median follow-up. Eur J Cancer 33:A877, 1997
Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H: Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50:731-741, 1991
Duffy M, Duggan C, Maguire T, McDermott E, O'Higgins N: Clinical significance of urokinase plasminogen activator and its receptor in breast cancer. Eur J Cancer 33:A879, 1997
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62:531-533, 1988
Klijn J, Berns E, Look M, van Gelder MM, Foekens J: Relationship of p53, uPA, pS2, EGF-R, and c-erbB-2, with response to systemic treatment in recurrent breast cancer patients. Eur J Cancer 33:A886, 1997
Athanassiadou P, Athanassiades P, Kyrkou K, Giahnaki E, Giannioti E, Nanas S: Expression of vimentin and epidermal growth factor receptor in effusions from patients with breast cancer; correlation with oestrogen and progesterone receptor status. Cytopathology 4:91-98, 1993
Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M: p53 protein and vimentin in invasive ductal NOS breast carcinoma — relationship with survival and sites of metastases. Eur J Cancer 30A:1527-1534, 1994
Chenard M-P, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq J-P, Duffy M: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 69:448-451, 1996
Daidone M, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini A, Garbisa S, Liotta L, Grigioni W: Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer 48:529-532, 1991
Duffy M, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly J, Tschesche H: Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 71:1025-1028, 1995
Linder C, Engel G, Auer G, Strander H, Linder S: Distribution of stromelysin-3 mRNA transcripts and microvessels in human breast carcinomas. Breast Cancer Res Treat 42:207-213, 1997
Russo A, Bazan V, Morello V, Tralongo V, Nagar C, Nuara R, Dardanoni G, Bazan P, Tomasino R: Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors: prognostic role in breast cancer. Anal Quant Cyt Hist 16:364-374, 1994
Seshadri R, Raymond W, Leong A, Horsfall D, McCaul K: Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 67:353-356, 1996
Stonelake P, Hail C, Jevons C, Baker P, Baker P: Proteinases and other prognostic markers in breast cancer. Br J Cancer 69:A83, 1994
Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A: Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 12A:1148-1155, 1996
Pellegrini R, Martignone S, Tagliabue E, Belotti D, Bufalino R, Cascinelli M, Mènard S, Colnaghi M: Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. Breast Cancer Res Treat 35:195-199, 1995
Martignone: Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 85:398-402, 1993
Marques LA, Franco EL, Torloni H, Brentani MM, Baptista da Silva-Neto J, Brentani RR: Prognostic value of laminin receptor expression in breast cancer survival. Cancer Res 50:1479-1483, 1990
Colnaghi M, Cascinelli N, Rilke F, Ménard S, Bufalino R, Andreola S, Martignone S, Greco M, Mascheroni L, Testori A: Predicting potential of c-erbB-2 oncoprotein and laminin receptor expression on primary breast cancer. Eur J Cancer 29Asuppl 6:S31, 1993
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
Gasparini G, Fox SB, Verderio P: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2:1191-1198, 1996
Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A:2485-2493, 1996
Axelsson K, Ljung B-M, Moore D, Thor A, Chew K, Edgerton S, Smith H, Mayall B: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87:997-1007, 1995
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred E, Moore D, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1888, 1992
Weidner N, Folkman J: Tumor vascularity as a prognostic factor in cancer. Principles and Practice of Oncology Updates 11:24, 1997
Vermeulen P, Libura J, Libura M, Hellemans P, Van Marck E, van Oosterom A, Dirix L: Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma [letter]. J Natl Cancer Inst 87:1797-1798, 1995
Fox S, Gatter K, Altman D, Leek R, Harris A: Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma [letter]. J Natl Cancer Inst 87:1798-1799, 1995
Gasparini G: Re: Tumor angiogenesis as a prognostic assay in invasive ductal carcinoma [Letter]. J Natl Cancer Inst 87:1799-1801, 1995
Axelsson K, Ljung B-M, Chew K, Mayall B, Moore D, Smith H, Thor A, Edgerton S: Re: Tumor angiogenesis as a prognostic assay in invasive ductal carcinoma [letter]. J Natl Cancer Inst 87:1801-1802, 1995
Heimann R, Ferguson D, Powers C, Recant W, Weichselbaum R, Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88:1764-1769, 1996
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-145, 1997
Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993
Bosari S, Lee A, DeLellis R, Wiley B, Heatley G, Silverman M: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
Vartanian R, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 144:1188-1194, 1994
Weidner N, Gasparini G: Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res Treat 29:97-107, 1994
Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
Siitonen S, Haapasalo H, Rantala I, Helin H, Isola J: Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 8:745-752, 1995
McCulloch P, Choy A, Martin L: Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334-1335, 1995
Ellis L, Fidler I: Angiogenesis and breast cancer metastasis. Lancet 346:388-389, 1995
Goulding H, Rashid N, Robertson J, Bell J, Elston C, Blamey R, Ellis I: Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 26:1196-1200, 1995
Relf M, LeJeune S, Scott P, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris A: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
Salvén P, Joensuu H, Heikkilä P, Matikainen M-T, Wasenius V-M, Alanko A, Alitalo K: Endothelial TIE growth factor provides antigenic marker for assessment of breast cancer angiogensis. Br J Cancer 74:69-72, 1996
Toi M, Hoshima S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
Lee W-J, Chu J-S, Houng S-J, Chung M-F, Wang S-M, Chen K-M: Breast cancer angiogenesis: A quantitative morphologic and doppler imaging study. Ann Surg Oncol 2:246-251, 1995
Gasparini G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla Palma P, Ménard S: 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 60:604-610, 1995
Obermair A, Kurtz C, Czerwenka K, Thoma M, Kaider A, Wagner T, Gitsch G, Selveda P: Microvessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62:126-131, 1995
Kato T, Kinura T, Miyakawa R, Tanaka S, Fujii A, Yamamoto K, Kameoka S, Hamano K, Kawakami M, Aiba M: Clinicopathologic study of angiogenesis in Japanese patients with breast cancer. World J Surg 21:49-56, 1997
Paulsen T, Aas T, Borresen A-L, Varhaug J, Lønning P, Akslen L: Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer 74:138-140, 1997
Morphopolous G, Pearson M, Ryder W, Howell A, Harris M: Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 180:44-49, 1996
Simpson J, Ahn C, Battifora H, Esteban J: Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 77:2077-2085, 1996
Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparini G: Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma — results of a multiparametric study. Breast Cancer Res Treat 36:205-217, 1995
Costello P, McCann A, Carney D, Dervan P: Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 26:1181-1194, 1995
Fox S, Leek R, Weekes M, Whitehouse R, Gatter K, Harris A: Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177:275-283, 1995
Karaiosifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S: Tumor angiogenesis in node-negative breast cancer: Relationship with relapse-free survival. Anticancer Res 16:4001-4002, 1996
Fox S, Turner G, Leek R, Whitehouse R, Gatter K, Harris A: The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat 36:219-226, 1995
Gasparini G, Harris A: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
Hall N, Fish D, Hunt N, Goldin R, Guillou P, Monson J: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1:223-229, 1992
Ogawa Y, Chung Y-S, Nakata B, Takatsuka S, Maede K, Sawade T, Kato Y, Yoshikawa K, Sakurai M, Sowa M: Microvessel quantitation in invasive breast cancer: staining for factor VIII-related antigen. Br J Cancer 71:1297-1301, 1995
Liotta L, Saidel G, Kleinerman J: The significance of intravascular tumor cell clumps in the metastatic process. Cancer Res 36:889-894, 1976
Smolin G, Hyundiuk R: Lymphatic drainage from vascularized rabbit cornea. Am J Opthamol 72:147-151, 1971
Viens P, Bertolucci F, Sun Z, Penault Llorca F, Bardou V, Geneix J, Jacquemier J: p53 overexpression and tumor angiogenesis are associated with treatment failure in women with breast cancer treated by a standard dose adjuvant chemotherapy. Proc AACR 38:A1579, 1997
Barnes D, Dublin E, Smith P, Miles DW, Rubens RD: Stabilized p53 protein and outcome following adjuvant CMF in 277 women with mammary carcinoma. Proc AACR 38:A1581, 1997
Fox S, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse R, Bicknell R, Gatter K, Harris A: The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73:275-280, 1996
Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, Kaider A, Leodolter S, Kainz C, Zeillinger R: Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74:455-458, 1997
Dirix L, Vermeulen P, Pawinski A, Prové A, Benoy I, de Pooler C, Martin M, van Oosterom A: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238-243, 1997
Bonneterre J, Peyrat J, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor-1 receptors in human breast cancer. Cancer Res 50:6931-6935, 1990
Railo M, van Smitten K, Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311, 1994
Berns E, Klijn J, van Staveren I, Portengen H, Foekens J: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036-1039, 1992
Liu F-F, Miller N, Levin W, Zanke B, Cooper B, Henry M, Sherrar M, Pintlie M, Hunt J, Hill R: The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. Int J Hypertherm 12:197-208, 1996
Love S, King R: A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 69:743-748, 1994
Tandon AK, Clark GM, Chamness GC, Fuqua SAW, Welch WJ, Riehl RM, McGuire WL: Heat shock/stress response proteins: biological and clinical significance in breast cancer. Proc ASCO 9:23, 1990
Solomayer E-F, Diel I, Gollan C, Wallweiner D, Gisecke F, Kaul S, Basert G: Tumor cell detection in breast cancer patients before and after neoadjuvant chemotherapy. Eur J Cancer 33:A342, 1997
Depenni R, Federico M, Morselli M, Luppi M, Cagossi K, Barbieri F, Torelli G, Silingardi V: Detection of circulating breast cancer cells by RTPCR of maspin gene: the mobilising effect of conventional chemotherapy. Proc ASCO 16:A487, 1997
Diel I, Gollan C, Wallweiner D, Basert G: Prognostic impact of minimal residual disease in patients with early breast cancer. Eur J Cancer 33:A340, 1997
Fox S, Leek R, Bliss J, Mansi J, Gusterson B, Gatter K, Harris A: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89:1044-1049, 1997
Mansi J, Berger U, Easton D, MacDonnell T, Redding W, Gazet J-C, McKinna A, Powles T, Coombes C: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295:1093, 1987
Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi M: Immunodetection of bone marrow metastases in breast carcinoma patients and its correlation with primary tumour prognostic features. Br J Cancer 66:1126-1129, 1994
Marcus J, Page D, Watson P, Narod S, Lenoir G, Lynch H: BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer 80:543-556, 1997
Jóhannsson O, Ranstam J, Borg Å, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
Krainer M, Silva-Arrieta S, Fitzgerald M, Shimada A, Ishioka C, Kanamaru R, MacDonald D, Unsal H, Finkelstein D, Bowcock A, Isselbacher K, Haber D: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997
Eisinger F, Lyonnet DS, Longy M, et al: Germ line mutation at BRCA1 affects histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474, 1996
Marcus J, Watson P, Page D, Narod S, Lenoir G, Tonin A, Linder-Stephenson L, Salerno G, Conway T, Lynch H: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996
Lynch H, Marcus J, Watson P, Page D: Distinctive clinicopathological features of BRCA-1 linked hereditary breast cancer. Proc ASCO 13:A27, 1994
Rights and permissions
About this article
Cite this article
Henderson, I.C., Patek, A.J. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52, 261–288 (1998). https://doi.org/10.1023/A:1006141703224
Issue Date:
DOI: https://doi.org/10.1023/A:1006141703224